By Jacob Gronholt-Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) -Years before Novo Nordisk's obesity drug Wegovy ...

It was a ‘mutual agreement,’ Novo says in a statement. A search for Fruergaard Jørgensen’s successor is ongoing.

Novo Nordisk has potential with a 27% upside, strong market shares, and high ROI strategies. See why we recommend a buy on ...

Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...

Wegovy-maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover ...

Polen Focus Growth Strategy stated the following regarding Novo Nordisk A/S (NYSE ... likely solidifying its potential as a future multi-billion-dollar drug, the drug’s profile appears less ...

Jørgensen will step down after eight years as CEO, with a successor search underway while the company reaffirms confidence in ...

The company behind the weight loss sensation that transformed bodies and bank accounts across America just showed its own CEO ...

Bundled Offer Includes Wegovy® at $199 and LifeMD's Virtual Weight Loss Program for a Total First-Month Cost of $299, $599 per Month Thereafter</p ...

Novo Nordisk A/S' CEO transition sparks governance concerns, but internal succession ensures stability. Click for my updated ...

U.S.-listed shares of Novo Nordisk declined in the opening minutes of trading Friday on the surprise news that CEO Lars ...

Septerna will also get royalties on any future product sales, The Wall Street Journal reported. Novo Nordisk will pay all the research and development costs for the project. The US biotech company ...